

#2
Docket No. 265084US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mauro NAPOLitano, et al.

SERIAL NO: 10/522,671

GAU:

FILED: January 28, 2005

EXAMINER:

FOR: MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 265084US0PCT		SERIAL NO. 10/522,671	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Mauro NAPOLETANO, et al.			
				FILING DATE January 28, 2005		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	3 478 014	11/11/69	DJOKIC et al.			
	AB	3 725 385	04/03/73	FREIBERG			
	AC	3 928 387	12/23/75	KIERSTEAD et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AD	92/16226	10/01/92	WO			NO
	AE	96/18633	06/20/96	WO			NO
	AF	97/00684	01/09/97	WO (with English abstract)			NO
	AG	99/16779	04/08/99	WO			NO
	AH	0 254 534	01/27/88	EP			NO
	AI	0 771 564	05/07/97	EP			NO
	AJ	0 775 489	05/28/97	EP			NO
	AK	0 941 998	09/15/99	EP			NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AL	TAKIZAWA, Hajime et al. "Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells", Am. J. Respir. Crit. Care Med., vol. 156, pages 266-271 1997					
	AM	TAMAOKI, Jun et al. "Macrolide Antibiotics Protect against Endotoxin-Induced Vascular Leakage and Neutrophil Accumulation in Rat Trachea", Antimicrobial Agents and Chemotherapy, vol. 38, no. 7, pages 1641-1643 1994					
	AN	SUZUKI, Tomoko et al. "Erythromycin and Common Cold in COPD", Chest, vol. 120, pages 730-733 2001					
	AO	LABRO, Marie Therese. "Immunomodulatory Actions of Antibacterial Agents", Clin. Immunother., vol. 6, pages 454-464 1996					
	AP	FAGHIIH, Ramin et al. "Synthesis and Antibacterial Activity of (9S)-9-Dihydroclarithromycin", Journal of Antibiotics, vol. 43, pages 1334-1336 1990					
	AQ	ANDERSON, Ronald et al. "Membrane-Stabilizing, Anti-Inflammatory Interactions of Macrolides with Human Neutrophils", Inflammation, vol. 20, no. 6, pages 693-705 1996					
	AR	STVRTINOVA, Viera et al. "Inflammation and Fever", Academic Electronic Press 1995					
	AS	WOODWARD, R.B. et al. "Asymmetric Total Synthesis of Erythromycin. 2. Synthesis of an Erythronolide A Lactone System", J. Am. Chem. Soc., vol. 103, no. 11, pages 3213-3215 1981					
	AT	FLYNN, Edwin H. et al. "Erythromycin. I. Properties and Degradation Studies", J. Am. Chem. Soc., vol. 76, pages 3121-3131 1954					
	AU	ZUNIC, Melita et al. "MDP(Lysyl)GDP, a Nontoxic Muramyl Dipeptide Derivative, Inhibits Cytokine Production by Activated Macrophages and Protects Mice from Phorbol Ester- and Oxazolone-Induced Inflammation", J. Invest. Dermatol., vol. 111, no. 1, pages 77-82 1998				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 265084US0PCT		SERIAL NO. 10/522,671	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Mauro NAPOLETANO, et al.			
				FILING DATE January 28, 2005		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AV	LABRO, M.T. "Anti-Inflammatory activity of macrolides: a new therapeutic potential?", Journal of Antimicrobial Chemotherapy, vol. 41, suppl. B, pages 37-46 1998					
	AW	MIKASA, Keiichi et al. "The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice", Journal of Antimicrobial Chemotherapy, vol. 30, pages 339-348 1992					
	AX	ABDELGHAFAR, H. et al. "Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro", Journal of Antimicrobial Chemotherapy, vol. 38, pages 81-93 1996					
	AY	LABRO, M.T. et al. "Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils", Journal of Antimicrobial Chemotherapy, vol. 24, pages 561-572 1989					
	AZ	KONNO, Shin-ichi et al. "Inhibition of Human T-Lymphocyte Activation by Macrolide Antibiotic. Roxithromycin", Life Sciences, vol. 51, pages PL231-236 1992					
	AAA	JORGENSEN, James H. et al. "Antibacterial Susceptibility Tests: Dilution and Disk Diffusion Methods", Manual of Clinical Microbiology, 7 th edition, pages 1526-1543 1999					
	AAB	SIGAL, Jr. Max V. et al. "Erythromycin. VI. Degradation Studies", J. Am. Chem. Soc., vol. 78, pages 388-395 1956					
	AAC	MIYATAKE, H. et al. "Erythromycin Reduces the Severity of Bronchial Hyperresponsiveness in Asthma", Chest, vol. 99, pages 670-673 1991					
	AAD	TAMAOKI, Jun et al. "Effect of Erythromycin on Endotoxin-Induced Microvascular Leakage in the Rat Trachea and Lungs", Am. J. Respir. Crit. Care Med., vol. 151, pages 1582-1588 1995					
	AAE	GASC, Jean-Claude et al. "New Ether Oxime Derivatives of Erythromycin A: A Structure-Activity Relationship Study", Journal of Antibiotics, vol. 44, no. 3, pages 313-330 1991					
	AAF	ABDELGHAFAR, Houria et al. "Erythromycin A-Derived Macrolides Modify the Functional Activities of Human Neutrophils by Altering the Phospholipase D-Phosphatidate Phosphohydrolase Transduction Pathway", Journal of Immunology, vol. 159, pages 3995-4005 1997					
	AAG	JAFFE, Adam et al. "Long-term azithromycin may improve lung function in children with cystic fibrosis", The Lancet, vol. 351, page 420 1998					
	AAH	O'NEIL, Maryadele J. et al. "Erythromycin", The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13 th edition, No. 3714, pages 654-655 2001					
	AAI	KOYAMA, Hiroshi et al. "Erythromycin and diffuse panbronchiolitis", Thorax, vol. 52, pages 915-918 1997					
	AAJ						
	AAK						
	AAL						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

U.S. PCT Application Serial No.: 10/522,671
Docket No.: 265084US0PCT

STATEMENT OF RELEVANCY

- 1) References _____ have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References _____ have been cited in the corresponding _____ Search Report. A copy of these references is being submitted herewith.
- 3) References AA-AAI are discussed in the specification. A copy of these references is being submitted here with.
- 4) References _____ are additional prior art known to Applicant. A copy of these references is being submitted herewith.